Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications

Drugs and Therapy Perspectives

Volumn 22, Issue 1, 2006, Pages 7-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; AMFEBUTAMONE; AMINOREX; AMPHETAMINE; DEXAMPHETAMINE; DEXFENFLURAMINE; EPHEDRA EXTRACT; EPHEDRINE; FENFLURAMINE; FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; MAZINDOL; PHENTERMINE; PHENYLPROPANOLAMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; TOPIRAMATE; ZONISAMIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANOREXIA; AUTONOMIC NEUROPATHY; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIET THERAPY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPHEDRA; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; KINESIOTHERAPY; LIFESTYLE; LIQUID FECES; LUNG PERFUSION; MALABSORPTION; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL NEUROPATHY; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT; STROKE; TACHYCARDIA; TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 31544476529     PISSN: 11720360     EISSN: 11720360     Source Type: Journal    
DOI: 10.2165/00042310-200622010-00003     Document Type: Review

References (25)

1. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65 (10): 1391-418
2. British national formulary. Sept 2005 No. 50 [online]. Available from URL:http://www.bnf.org [Accessed 2005 Oct 12]
3. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication no. 98-4083. Washington, DC: US Government Press, 1998 Sep
4. Wadden TA, Berkowitz RI, Womble LG, et al.Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 Nov 17; 353 (20): 2111-20
5. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968; 1: 352-4
6. Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res Clin Exp 1972; 14: 726-38
7. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289: 1537-45
8. US Food and Drug Administration. Dietary supplements containing ephedrine alkaloids: final rule summary [online]. Available from URL: http://www.fda.gov [Accessed 2005 Oct 12]
9. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873-83
10. Aydin N, Topsever P, Kaya A, et al. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004; 202: 173-80
11. Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 6: 431-7
12. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf 1999; 20 (2): 119-31
13. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; 3: CD004094
14. Hauner H, Meier M, Jockel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453-9
15. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116-23
16. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5-11
17. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160 (14): 2185-91
18. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61
19. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049-56
20. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633-41
21. Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129-35
22. Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321-5
23. Griffen L, Anchors M. The "Phen-Pro" diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158: 1278-9
24. Gadde KM, Franciscy DM, Wagner II HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289: 1820-5
25. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97